12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Status:
Terminated
Trial end date:
2017-03-20
Target enrollment:
Participant gender:
Summary
People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of
the infection when they are treated with sofosbuvir. However, in some instances, treatment
with sofosbuvir-containing therapy does not work. It is not known if people respond to
retreatment with sofosbuvir, after it did not work the first time. There is an important need
to understand retreatment options in those instances. This clinical trial was done to study
the response to two different regimens, ledipasvir/sofosbuvir and ledipasvir/sofosbuvir with
ribavirin, and to see if they are safe and well-tolerated in HCV-infected persons whose
previous treatment with sofosbuvir had failed.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Ribavirin Sofosbuvir